These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7894125)

  • 1. [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes].
    Chazard M; Pellae-Cosset B; Garet F; Soares JA; Lucidi B; Lavail Y; Lenaz L
    Bull Cancer; 1994 Mar; 81(3):173-81. PubMed ID: 7894125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of Taxol.
    Arbuck SG; Christian MC; Fisherman JS; Cazenave LA; Sarosy G; Suffness M; Adams J; Canetta R; Cole KE; Friedman MA
    J Natl Cancer Inst Monogr; 1993; (15):11-24. PubMed ID: 7912517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R; Vorlicek J; Slavik M
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paclitaxel (Taxol)].
    Hájek R
    Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration.
    Yeung TK; Germond C; Chen X; Wang Z
    Biochem Biophys Res Commun; 1999 Sep; 263(2):398-404. PubMed ID: 10491305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological action of paclitaxel].
    Potemski P; Płuzańska A
    Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
    Hawkins MJ
    Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials referral resource. Clinical trials with taxol.
    Cheson BD
    Oncology (Williston Park); 1992 Mar; 6(3):67-70. PubMed ID: 1348954
    [No Abstract]   [Full Text] [Related]  

  • 12. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
    Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
    Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
    Schalhorn B
    Med Klin Suppl; 1993 Nov; 2():4-6. PubMed ID: 7904718
    [No Abstract]   [Full Text] [Related]  

  • 17. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microtubules and antineoplastic drugs].
    Arioka H; Saijo N
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.